This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 2/6/532    most recent CIRCHEARTFAILURE.109.861336v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Rademaker, M. T. Articles by Richards, A. M. PubMed PubMed Citation Articles by Rademaker, M. T. Articles by Richards, A. M. Related Collections Congestive Cardiovascular Pharmacology Animal models of human disease

Original Articles

Urocortin 2 Inhibits Furosemide-Induced Activation of Renin and Enhances Renal Function and Diuretic Responsiveness in Experimental Heart Failure

Miriam T. Rademaker, PhD; Christopher J. Charles, PhD; M. Gary Nicholls, MD, FRACP and A. Mark Richards, MD, PhD, FRACP

From the Christchurch Cardioendocrine Research Group, Christchurch School of Medicine, Christchurch, New Zealand.

Correspondence to Miriam Rademaker, PhD, Department of Medicine, The Christchurch School of Medicine, PO Box 4345, Christchurch, New Zealand. E-mail miriam.rademaker{at}chmeds.ac.nz

Received March 1, 2009; accepted August 7, 2009.

Background— Urocortin 2 (Ucn2), a novel peptide with therapeutic potential in heart failure, and diuretics have opposing effects on renal function and the renin-angiotensin-aldosterone system. Because any prospective new treatment is likely to be used in conjunction with standard diuretic therapy, it is necessary to investigate the combined effects of these agents.

Methods and Results— Ucn2 and furosemide were administered for 3 hours, both singly and combined, in 7 sheep with pacing-induced heart failure. Compared with time-matched controls, separate Ucn2 and furosemide administration significantly increased urine output (furosemide>Ucn2), urine sodium (furosemide>Ucn2), potassium (furosemide>Ucn2), and creatinine excretion (Ucn2>furosemide) and creatinine clearance (Ucn2>furosemide). Compared with furosemide treatment alone, Ucn2+furosemide produced a further diuresis (P<0.05), natriuresis (P<0.05), and a sustained increase in creatinine excretion (P<0.05) and clearance (P<0.05), without additional potassium elimination. All active treatments reduced mean arterial pressure (Ucn2+furosemide=furosemide>Ucn2), left atrial pressure (Ucn2+furosemide>Ucn2>furosemide), and peripheral resistance (Ucn2+furosemide=Ucn2>furosemide), whereas only Ucn2, singly and in combination with furosemide, increased cardiac output and dP/dt(max). In contrast to the increase in plasma renin activity elicited by furosemide alone, Ucn2 and Ucn2+furosemide markedly reduced plasma renin activity. All active treatments decreased plasma aldosterone (Ucn2+furosemide=Ucn2>furosemide), whereas only Ucn2 and Ucn2+furosemide reduced vasopressin and natriuretic peptide concentrations.

Conclusion— Ucn2 cotreatment with furosemide enhanced hemodynamic and renal function and diuretic responsiveness (without additional potassium depletion) in experimental heart failure. Furthermore, Ucn2 reversed furosemide-induced increases in plasma renin activity and induced greater decreases in plasma aldosterone and vasopressin. These data indicate that adjunct Ucn2 therapy with diuretics in heart failure is beneficial.

Key Words: urocortin 2 • diuretics • heart failure • hemodynamics • hormones • renal function

---

 

CLINICAL PERSPECTIVE